Large Scale Biology Corp, formerly known as Proteus Technologies Inc, ceased business operations in June 2004: bankrupt and assets sold. Along with the wholly owned subsiduary Predictive Diagnostics Inc. -- clinical proteomics; formerly called Eclipse Diagnostics-- the company had provided protein-focused technologies and information to enable the accelerated identification, development, and production of new and improved products for the life sciences industry. The firm went public on NASDAQ in 2000 but ;ater moved to OTC The firm's protein technologies enabled the transformation of genomic information into products such as drug targets, therapeutics, diagnostics for drug efficacy and toxicity, and traits for agricultural crops. Large Scale had been trying to produce biotech drugs in tobacco plants with its most advanced experimental product having been a vaccine to treat non-Hodgkin's lymphoma. LSB's proprietary protein technologies had the potential to enable the transformation of genomic information into products such as drug targets, therapeutics, diagnostics for drug efficacy and toxicity, but also traits for agricultural crops. Had had a substantial in-place relationship to Dow Chemical
